Which diabetes pill is better for your heart? huge study aims to find out

NCT ID NCT07390110

Ongoing Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This large study compares two diabetes drugs—oral semaglutide and sitagliptin—in over 25,000 people with type 2 diabetes and heart failure. Researchers want to see which drug better prevents heart failure worsening or death. The study uses existing medical records to mimic a clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral semaglutide and sitagliptin
What this could lead to: If this study shows one drug works better, it could guide doctors to a more effective treatment for heart failure in people with diabetes.
What could go wrong: This is an observational study using existing data, not a controlled trial. Results may be affected by unmeasured differences between groups, so they cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE TYPE 2 DIABETES

Contacts and locations

Show contact details

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.